Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice

[1] Pinsky P(2017)Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years Cancer 123 592-599

[2] Prorok P(2012)US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement Ann Intern Med 157 120-134

[3] Yu K(2012)Prostate specific antigen screening for prostate cancer: knowledge of attitudes towards, and utilization among primary care physicians Urol Oncol 30 155-160

[4] Moyer VA(2018)US Preventive Services Task Force: Screening for prostate cancer: US Preventive Services Task Force recommendation statement JAMA 319 1901-1913

[5] Tasian GE(2015)Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations JAMA 314 2054-2061

[6] Cooperberg MR(2015)Decrease in prostate cancer testing following the US Preventive Services Task Force (USPSTF) recommendations J Am Board Fam Med 28 491-493

[7] Cowan JE(2015)Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations JAMA 314 2077-2079

[8] Grossman DC(2015)National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendations J Clin Oncol 33 2416-2423

[9] Jemal A(2016)Contemporary national trends of prostate cancer screening among privately insured men in the United States Urology 97 111-117

[10] Fedewa SA(2017)Impact of prostate-specific antigen (PSA) screening trials, and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications Eur Urol 71 55-65

[1] Pinsky P(2017)Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years Cancer 123 592-599

[2] Prorok P(2012)US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement Ann Intern Med 157 120-134

[3] Yu K(2012)Prostate specific antigen screening for prostate cancer: knowledge of attitudes towards, and utilization among primary care physicians Urol Oncol 30 155-160

[4] Moyer VA(2018)US Preventive Services Task Force: Screening for prostate cancer: US Preventive Services Task Force recommendation statement JAMA 319 1901-1913

[5] Tasian GE(2015)Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations JAMA 314 2054-2061

[6] Cooperberg MR(2015)Decrease in prostate cancer testing following the US Preventive Services Task Force (USPSTF) recommendations J Am Board Fam Med 28 491-493

[7] Cowan JE(2015)Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations JAMA 314 2077-2079

[8] Grossman DC(2015)National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendations J Clin Oncol 33 2416-2423

[9] Jemal A(2016)Contemporary national trends of prostate cancer screening among privately insured men in the United States Urology 97 111-117

[10] Fedewa SA(2017)Impact of prostate-specific antigen (PSA) screening trials, and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications Eur Urol 71 55-65